SU1453661A1 - Противоопухолевое средство "продимин - Google Patents
Противоопухолевое средство "продимин Download PDFInfo
- Publication number
- SU1453661A1 SU1453661A1 SU721848995A SU1848995A SU1453661A1 SU 1453661 A1 SU1453661 A1 SU 1453661A1 SU 721848995 A SU721848995 A SU 721848995A SU 1848995 A SU1848995 A SU 1848995A SU 1453661 A1 SU1453661 A1 SU 1453661A1
- Authority
- SU
- USSR - Soviet Union
- Prior art keywords
- patients
- treatment
- drug
- course
- patient
- Prior art date
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 claims 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 2
- BCDAVFWCNYQBBF-UHFFFAOYSA-N 3-bromo-n-[2-(3-bromopropanoylamino)ethyl]propanamide Chemical compound BrCCC(=O)NCCNC(=O)CCBr BCDAVFWCNYQBBF-UHFFFAOYSA-N 0.000 abstract 1
- IHBVNSPHKMCPST-UHFFFAOYSA-N 3-bromopropanoyl chloride Chemical compound ClC(=O)CCBr IHBVNSPHKMCPST-UHFFFAOYSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 26
- 229940079593 drug Drugs 0.000 description 25
- 150000001875 compounds Chemical class 0.000 description 15
- 210000000265 leukocyte Anatomy 0.000 description 15
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 230000007423 decrease Effects 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 210000000952 spleen Anatomy 0.000 description 8
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 7
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 208000025036 lymphosarcoma Diseases 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 210000005259 peripheral blood Anatomy 0.000 description 5
- 239000011886 peripheral blood Substances 0.000 description 5
- 208000008601 Polycythemia Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 238000005534 hematocrit Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 208000037244 polycythemia vera Diseases 0.000 description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 229960001334 corticosteroids Drugs 0.000 description 3
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 3
- 230000005713 exacerbation Effects 0.000 description 3
- 230000002489 hematologic effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000035987 intoxication Effects 0.000 description 3
- 231100000566 intoxication Toxicity 0.000 description 3
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 210000001995 reticulocyte Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 208000004860 Blast Crisis Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- 208000005485 Thrombocytosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000719 anti-leukaemic effect Effects 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 210000003969 blast cell Anatomy 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 239000000824 cytostatic agent Substances 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 210000003979 eosinophil Anatomy 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- QZJPEEOEZVHUAE-UHFFFAOYSA-L prospidium chloride Chemical compound [Cl-].[Cl-].C1CN(CC(CCl)O)CC[N+]21CC[N+]1(CCN(CC(O)CCl)CC1)CC2 QZJPEEOEZVHUAE-UHFFFAOYSA-L 0.000 description 2
- 229960004528 vincristine Drugs 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
- DIEFOGBIJXJDBG-UHFFFAOYSA-N 2-bromo-n-[2-(2-bromopropanoylamino)ethyl]propanamide Chemical compound CC(Br)C(=O)NCCNC(=O)C(C)Br DIEFOGBIJXJDBG-UHFFFAOYSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- ZRKWMRDKSOPRRS-UHFFFAOYSA-N N-Methyl-N-nitrosourea Chemical compound O=NN(C)C(N)=O ZRKWMRDKSOPRRS-UHFFFAOYSA-N 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000002986 anti-lethal effect Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000009096 combination chemotherapy Methods 0.000 description 1
- -1 cshklofosfan Chemical compound 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 210000001237 metamyelocyte Anatomy 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 229940124583 pain medication Drugs 0.000 description 1
- 210000003481 parotid region Anatomy 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 208000012284 reactive thrombocytosis Diseases 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010911 splenectomy Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU721848995A SU1453661A1 (ru) | 1972-11-17 | 1972-11-17 | Противоопухолевое средство "продимин |
| GB4001273A GB1428044A (en) | 1972-11-17 | 1973-08-23 | Antitumorigenic compositions |
| DE19732343809 DE2343809A1 (de) | 1972-11-17 | 1973-08-30 | Arzneimittel mit antigeschwulstwirkung |
| FR7339101A FR2206938B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1972-11-17 | 1973-11-02 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SU721848995A SU1453661A1 (ru) | 1972-11-17 | 1972-11-17 | Противоопухолевое средство "продимин |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SU1453661A1 true SU1453661A1 (ru) | 1989-10-30 |
Family
ID=20532792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SU721848995A SU1453661A1 (ru) | 1972-11-17 | 1972-11-17 | Противоопухолевое средство "продимин |
Country Status (4)
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2456983C2 (ru) * | 2006-11-28 | 2012-07-27 | Новартис Аг | Комбинация ингибиторов iap и flt3 |
| RU2605603C1 (ru) * | 2015-06-19 | 2016-12-27 | Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) | N,n'-бис(3-бромпропионил)-n,n'-диметил-1,2-этилендиамин, способ его получения и применение его в качестве водорастворимого реагента, проявляющего противоопухолевые свойства |
-
1972
- 1972-11-17 SU SU721848995A patent/SU1453661A1/ru active
-
1973
- 1973-08-23 GB GB4001273A patent/GB1428044A/en not_active Expired
- 1973-08-30 DE DE19732343809 patent/DE2343809A1/de active Pending
- 1973-11-02 FR FR7339101A patent/FR2206938B1/fr not_active Expired
Non-Patent Citations (1)
| Title |
|---|
| Prod.et probl.pharm., , № 4, р,276. * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2456983C2 (ru) * | 2006-11-28 | 2012-07-27 | Новартис Аг | Комбинация ингибиторов iap и flt3 |
| RU2605603C1 (ru) * | 2015-06-19 | 2016-12-27 | Федеральное государственное бюджетное учреждение науки Институт проблем химической физики Российской академии наук (ИПХФ РАН) | N,n'-бис(3-бромпропионил)-n,n'-диметил-1,2-этилендиамин, способ его получения и применение его в качестве водорастворимого реагента, проявляющего противоопухолевые свойства |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2206938B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1977-02-18 |
| GB1428044A (en) | 1976-03-17 |
| FR2206938A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1974-06-14 |
| DE2343809A1 (de) | 1974-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Robinson et al. | Treatment of metastatic malignant melanoma with recombinant interferon alpha 2 | |
| Creagan et al. | Phase II study of recombinant leukocyte A interferon (rIFN‐αA) in disseminated malignant melanoma | |
| Poplack et al. | Phase I study of 2′-deoxycoformycin in acute lymphoblastic leukemia | |
| Dover et al. | Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production | |
| Selawry et al. | Vincristine treatment of cancer in children | |
| Allen et al. | Oxymetholone therapy in aplastic anemia | |
| Rosenthal et al. | The use of adrenocorticotropic hormone and cortisone in the treatment of leukemia and leukosarcoma | |
| EP0774255B1 (en) | Use of ursolic acid for the manufacture of a medicament for suppressing metastasis | |
| Teklu et al. | Meptazinol diminishes the Jarisch-Herxheimer reaction of relapsing fever | |
| EP1443933B1 (en) | Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents | |
| Sokal et al. | Evidence for a selective antileukemic effect of cytosine arabinoside in chronic granulocytic leukemia | |
| US4806347A (en) | Interferon combinations | |
| Nissen et al. | Phase I Clinical Trial of an Oral Solution of VP-16-2131, 2 | |
| SU1453661A1 (ru) | Противоопухолевое средство "продимин | |
| Martoni et al. | Activity of 4-demethoxydaunorubicin by the oral route in advanced breast cancer | |
| PT99265B (pt) | Processo para a preparacao de composicoes farmaceuticas contendo interferon humano e metodo de tratamento de doencas proliferativas celulares | |
| Kakimoto et al. | Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome | |
| Shimkin et al. | Trisethylene-imino-s-triazine (triethylene melamine or TEM) in the treatment of neoplastic diseases | |
| Wong et al. | Comparative effects of tetrandrine and berbamine on acute and relapsing experimental allergic encephalitis in Lewis rats | |
| JPH06234636A (ja) | インターロイキン８を阻害するためのレフルノミドの使用 | |
| Bershof et al. | AGRANULOCYTOSIS FOLLOWING USE OF PHENYLBUTAZONE (BUTAZOLIDIN9): REPORT OF A CASE | |
| Suzuki et al. | Pure white cell aplasia complicated by systemic sclerosis with accompanying scleroderma renal crisis | |
| DE4127469A1 (de) | Arzneimittel und ihre verwendung | |
| CA2229141A1 (en) | Combination therapy for advanced cancer comprising temozolomide and cisplatin | |
| Epstein | Synthetic antimalarial drug therapy in lupus erythematosus and polymorphous light eruptions |